Enoki Miho, Saito Jun, Hara Makiko, Uchida Tetsuya, Sagara Takeshi, Nishida Teruo
Department of Ophthalmology, Ogori Daiichi General Hospital, Ogori, Yamaguchi, Japan.
Department of Biomolecular Recognition and Ophthalmology, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan.
Jpn J Ophthalmol. 2006 Jul-Aug;50(4):334-337. doi: 10.1007/s10384-005-0334-5.
To determine whether treatment with latanoprost eye drops is able to further reduce intraocular pressure (IOP) in normal-tension glaucoma (NTG) patients whose IOP has been well controlled with unoprostone.
A total of 34 eyes (34 individuals) with NTG that had been treated with 0.12% unoprostone eye drops twice daily for >or=3 months were switched to treatment once daily with eye drops containing 0.005% latanoprost. IOP was measured before and 1, 2, and 3 months after the switch to latanoprost.
The mean IOP of all eyes was decreased significantly by 1.8, 2.9, and 2.3 mmHg at 1, 2, and 3 months after the switch from unoprostone to latanoprost treatment. The IOP of patients with an initial IOP of <or=12 or >12 mmHg was reduced by 11.0 or 19.9%, respectively, after 3 months on latanoprost. The IOP of 30 (88.2%) of the 34 eyes was further reduced by the switch from unoprostone to latanoprost.
Latanoprost reduced the IOP of NTG patients who had already been treated with unoprostone, even though both drugs are prostaglandin-related. Switching to latanoprost might thus achieve a maximal decrease in IOP and thereby better prevent damage to the optic nerve and loss of visual field in NTG patients.
确定对于眼压已通过乌诺前列酮良好控制的正常眼压性青光眼（NTG）患者，使用拉坦前列素滴眼液治疗是否能够进一步降低眼压（IOP）。
共有34只眼（34例患者）患有NTG，这些患者每日两次使用0.12%乌诺前列酮滴眼液治疗≥3个月，之后改为每日一次使用含0.005%拉坦前列素的滴眼液。在改用拉坦前列素之前以及之后1、2和3个月测量眼压。
从乌诺前列素改为拉坦前列素治疗后1、2和3个月，所有眼睛的平均眼压分别显著降低了1.8、2.9和2.3 mmHg。初始眼压≤12或>12 mmHg的患者在使用拉坦前列素3个月后，眼压分别降低了11.0%或19.9%。34只眼中有30只眼（88.2%）从乌诺前列素改用拉坦前列素后眼压进一步降低。
拉坦前列素降低了已接受乌诺前列素治疗的NTG患者的眼压，尽管这两种药物都与前列腺素相关。因此，改用拉坦前列素可能实现眼压的最大降幅，从而更好地预防NTG患者的视神经损伤和视野丧失。
